| Dr Colby Scott Engar, MD | |
|
1303 N Main St, Cedar City, UT 84721-9746 | |
| (435) 868-5300 | |
| Not Available |
| Full Name | Dr Colby Scott Engar |
|---|---|
| Gender | Male |
| Speciality | Diagnostic Radiology |
| Experience | 16 Years |
| Location | 1303 N Main St, Cedar City, Utah |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1659518678 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2085R0202X | Radiology - Diagnostic Radiology | 5073535-1205 (Utah) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Intermountain Medical Center | Murray, UT | Hospital |
| Mckay Dee Hospital | Ogden, UT | Hospital |
| Riverton Hospital | Riverton, UT | Hospital |
| Lds Hospital | Salt lake city, UT | Hospital |
| Cedar City Hospital | Cedar city, UT | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Intermountain Healthcare Services, Inc | 1850209420 | 3063 |
News Archive
In a new research study under way at the Methodist DeBakey Heart & Vascular Center, surgeons are adding a patient's own stem cells to the heart during cardiac bypass surgery. The goal of this research study is to determine whether the stem cell infusion will generate new blood vessels and improve heart function more than what is seen through bypass surgery alone.
With 'stop smoking' high on many people's New Year's resolution list, Huddersfield researchers use eye-tracking methods to determine the effectiveness of the health warnings on packets. The study compared older-style packets with the new regulation designs.
CeNeRx BioPharma, Inc., a clinical stage company developing and commercializing innovative treatments for diseases of the central nervous system (CNS), today announced completion of a $13 million Series C financing. Existing investors Perseus Soros Biopharmaceutical Fund, L Capital Partners and Pappas Ventures all participated in the financing. CeNeRx plans to use the proceeds to conduct a Phase II trial of its improved formulation of its novel antidepressant TriRima™.
Researchers at Aalto University have developed a method of selection of new surface treatment processes for orthopaedic and dental implants to reduce the risk of infection.
The Food and Drug Administration in the United States is coming under increasing pressure to enforce tougher regulations on the amount of sodium in food.
› Verified 1 days ago
| Entity Name | Ihc Health Services Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1629260880 PECOS PAC ID: 1850209420 Enrollment ID: O20031105000079 |
News Archive
In a new research study under way at the Methodist DeBakey Heart & Vascular Center, surgeons are adding a patient's own stem cells to the heart during cardiac bypass surgery. The goal of this research study is to determine whether the stem cell infusion will generate new blood vessels and improve heart function more than what is seen through bypass surgery alone.
With 'stop smoking' high on many people's New Year's resolution list, Huddersfield researchers use eye-tracking methods to determine the effectiveness of the health warnings on packets. The study compared older-style packets with the new regulation designs.
CeNeRx BioPharma, Inc., a clinical stage company developing and commercializing innovative treatments for diseases of the central nervous system (CNS), today announced completion of a $13 million Series C financing. Existing investors Perseus Soros Biopharmaceutical Fund, L Capital Partners and Pappas Ventures all participated in the financing. CeNeRx plans to use the proceeds to conduct a Phase II trial of its improved formulation of its novel antidepressant TriRima™.
Researchers at Aalto University have developed a method of selection of new surface treatment processes for orthopaedic and dental implants to reduce the risk of infection.
The Food and Drug Administration in the United States is coming under increasing pressure to enforce tougher regulations on the amount of sodium in food.
› Verified 1 days ago
| Entity Name | Tellica Imaging Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1760197198 PECOS PAC ID: 3577950765 Enrollment ID: O20231201000761 |
News Archive
In a new research study under way at the Methodist DeBakey Heart & Vascular Center, surgeons are adding a patient's own stem cells to the heart during cardiac bypass surgery. The goal of this research study is to determine whether the stem cell infusion will generate new blood vessels and improve heart function more than what is seen through bypass surgery alone.
With 'stop smoking' high on many people's New Year's resolution list, Huddersfield researchers use eye-tracking methods to determine the effectiveness of the health warnings on packets. The study compared older-style packets with the new regulation designs.
CeNeRx BioPharma, Inc., a clinical stage company developing and commercializing innovative treatments for diseases of the central nervous system (CNS), today announced completion of a $13 million Series C financing. Existing investors Perseus Soros Biopharmaceutical Fund, L Capital Partners and Pappas Ventures all participated in the financing. CeNeRx plans to use the proceeds to conduct a Phase II trial of its improved formulation of its novel antidepressant TriRima™.
Researchers at Aalto University have developed a method of selection of new surface treatment processes for orthopaedic and dental implants to reduce the risk of infection.
The Food and Drug Administration in the United States is coming under increasing pressure to enforce tougher regulations on the amount of sodium in food.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Colby Scott Engar, MD 1303 N Main St, Cedar City, UT 84721-9746 Ph: (435) 868-5300 | Dr Colby Scott Engar, MD 1303 N Main St, Cedar City, UT 84721-9746 Ph: (435) 868-5300 |
News Archive
In a new research study under way at the Methodist DeBakey Heart & Vascular Center, surgeons are adding a patient's own stem cells to the heart during cardiac bypass surgery. The goal of this research study is to determine whether the stem cell infusion will generate new blood vessels and improve heart function more than what is seen through bypass surgery alone.
With 'stop smoking' high on many people's New Year's resolution list, Huddersfield researchers use eye-tracking methods to determine the effectiveness of the health warnings on packets. The study compared older-style packets with the new regulation designs.
CeNeRx BioPharma, Inc., a clinical stage company developing and commercializing innovative treatments for diseases of the central nervous system (CNS), today announced completion of a $13 million Series C financing. Existing investors Perseus Soros Biopharmaceutical Fund, L Capital Partners and Pappas Ventures all participated in the financing. CeNeRx plans to use the proceeds to conduct a Phase II trial of its improved formulation of its novel antidepressant TriRima™.
Researchers at Aalto University have developed a method of selection of new surface treatment processes for orthopaedic and dental implants to reduce the risk of infection.
The Food and Drug Administration in the United States is coming under increasing pressure to enforce tougher regulations on the amount of sodium in food.
› Verified 1 days ago
Shane Arthur Baker, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 1303 N Main St, Cedar City, UT 84721 Phone: 435-868-5000 |